Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIVAP: Shingrix vaccination in patients with psoriasis or psoriatic arthritis
2022-003477-36Phase 4Active
- Sponsor
- Justus Liebig University Giessen
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by Justus Liebig University Giessen. Primary endpoint: Increase in psoriasis or psoriatic arthritis activity after Shingrix vaccination. Started Jan 2023; status: active.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2022-003477-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003477-36.